Virpax Pharmaceuticals Inc (NASDAQ: VRPX) has seen a decline in its stock price by -6.69 in relation to its previous close of 0.18. However, the company has experienced a -14.16% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-03-07 that BERWYN, Pa.–(BUSINESS WIRE)–Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look t.
Is It Worth Investing in Virpax Pharmaceuticals Inc (NASDAQ: VRPX) Right Now?
Company’s 36-month beta value is 1.09.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VRPX is 26.13M, and currently, short sellers hold a 3.66% ratio of that floaft. The average trading volume of VRPX on March 14, 2025 was 5.55M shares.
VRPX’s Market Performance
VRPX’s stock has seen a -14.16% decrease for the week, with a -38.11% drop in the past month and a -46.42% fall in the past quarter. The volatility ratio for the week is 6.26%, and the volatility levels for the past 30 days are at 12.21% for Virpax Pharmaceuticals Inc The simple moving average for the past 20 days is -26.65% for VRPX’s stock, with a -73.69% simple moving average for the past 200 days.
VRPX Trading at -41.14% from the 50-Day Moving Average
After a stumble in the market that brought VRPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.56% of loss for the given period.
Volatility was left at 12.21%, however, over the last 30 days, the volatility rate increased by 6.26%, as shares sank -42.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.37% lower at present.
During the last 5 trading sessions, VRPX fell by -14.11%, which changed the moving average for the period of 200-days by -77.07% in comparison to the 20-day moving average, which settled at $0.2264. In addition, Virpax Pharmaceuticals Inc saw -56.28% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VRPX
The total capital return value is set at 13.22. Equity return is now at value -2364.82, with -215.80 for asset returns.
Currently, EBITDA for the company is -12.08 billion with net debt to EBITDA at 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
In a nutshell, Virpax Pharmaceuticals Inc (VRPX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
